Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maxigen BiotechTPE:1783 +0.13%92 Return-on-Tangible-Asset is 10.88% as of Mar. 2026, which is 57% above its 10-year median of 6.91. GuruFocus rates TPE:1783 with a GF Score™ of 92/100 and a GF Value™ of NT$59.40 (Significantly Undervalued). Among 854 Medical Devices & Instruments companies, Maxigen Biotech ranks better than 91.69% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Maxigen Biotech's annualizedNet Income for the quarter that ended in Mar. 2026 was NT$211.2 Mil. Maxigen Biotech's average total tangible assets for the quarter that ended in Mar. 2026 was NT$1,941.3 Mil. Therefore, Maxigen Biotech's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 10.88%.
The historical rank and industry rank for Maxigen Biotech's Return-on-Tangible-Asset or its related term are showing as below:
TPE:1783'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1.08 Med: 6.91 Max: 15.27
Current: 15.09
During the past 13 years, Maxigen Biotech's highest Return-on-Tangible-Asset was 15.27%. The lowest was -1.08%. And the median was 6.91%.
TPE:1783's Return-on-Tangible-Asset is ranked better than 91.69% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.665
vs TPE:1783: 15.09
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Maxigen Biotech Return-on-Tangible-Asset Related Terms
Maxigen Biotech Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1783 vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 10.88% mean?
Maxigen Biotech (TPE:1783) has a Return-on-Tangible-Asset of 10.88% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Maxigen Biotech and its competitors. This is 57% above median its historical median of 6.91. According to the industry distribution chart, Maxigen Biotech ranks #71 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 8.3%.
Is Maxigen Biotech's Return-on-Tangible-Asset too high?
Maxigen Biotech's current Return-on-Tangible-Asset of 10.88% is 57% above median its 10-year median of 6.91. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.67. Maxigen Biotech's value of 10.88% is 1536.1% above this industry median. Based on the distribution chart, Maxigen Biotech ranks #71 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Maxigen Biotech has a GF Score™ of 92/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #71 out of 854 companies for Return-on-Tangible-Asset. This places Maxigen Biotech in the top 8% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.67. Maxigen Biotech's value of 10.88% is 1536.1% above this benchmark. While the company's 10-year median is 6.91 vs. the industry median of 0.67, Maxigen Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.67, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maxigen Biotech's current Return-on-Tangible-Asset of 10.88% is 1536.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Maxigen Biotech and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current Return-on-Tangible-Asset is 10.88%, which is 57% above median its own 10-year median of 6.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$59.40, compared to a current price of NT$39.85 — trading 32.9% below its estimated fair value. The current Return-on-Tangible-Asset is 10.88%, which is 57% above median its 10-year median of 6.91 and 1536.1% above the Medical Devices & Instruments industry median of 0.67. Maxigen Biotech's overall GF Score™ is 92/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current Return-on-Tangible-Asset is 10.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$39.85 is trading 32.9% below its estimated GF Value™ of NT$59.40.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
Return-on-Tangible-Asset: 10.88% (57% above median its 10-year median of 6.91)
GF Value™: NT$59.40 vs. price of NT$39.85 (32.9% below fair value)
Industry Position: 1536.1% above the Medical Devices & Instruments median (#71 of 854)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
92GF Score
Get the complete analysis for TPE:1783
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
